Treatment of resistance to Pitolisant-wakix

Although Pitolisant-wakix treatment is generally well tolerated, its safety profile cannot be compared with that of active agents with similar pharmacodynamics because it is the first antagonist/inverse agonist H3R used clinically. Tilolixen tablets have been approved in the European Union for the treatment of narcolepsy with or without cataplexy and have been designated as orphan drugs by the European Medicines Agency and the U.S. Food and Drug Administration.

Drug resistance is a complex issue that requires the consideration of multiple factors. Try using an alternative drug that has a different mechanism of action. This can help reduce the risk of drug resistance and maintain drug efficacy. Please consult your doctor for appropriate rotational medication options. Combining tilolixen tablets with other medications may enhance efficacy and delay the emergence of resistance. Discuss possible combination treatment options with your doctor to ensure the safety and suitability of the drug combination. Use tilorisen tablets correctly as recommended by your doctor. Observe the correct dosage and timing and do not increase or decrease the dosage on your own. At the same time, follow the prescribed dosing intervals to ensure that the concentration of the drug in the body remains stable. Monitor drug efficacy and drug resistance regularly. This may be accomplished through clinical assessment, laboratory examination, or other relevant testing. Early detection of signs of drug resistance can prompt doctors to adjust treatment plans in a timely manner.

Tilorisen tablets have been marketed in the country, but have not yet been included in medical insurance. The price of each box of the original version of tilorisen tablets marketed overseas may be over more than RMB 4,000 (the price may fluctuate due to exchange rates). Currently, there are no generic versions of tilorisen tablets produced and marketed overseas.